Stereotaxis to Report Third Quarter 2019 Financial Results on November 14, 2019
November 06 2019 - 9:00AM
Stereotaxis, Inc. (NYSE American: STXS) the global leader in
innovative robotic technologies for the treatment of cardiac
arrhythmias, today announced that it will release financial results
for its 2019 third quarter ended September 30, 2019 on November 14,
2019 before the open of the U.S. financial markets. The Company
will host a conference call and webcast at 9:00 a.m. Eastern Time
that day to discuss the Company’s results and corporate
developments.
What: |
Stereotaxis third quarter 2019 financial results conference
call |
|
|
When: |
November 14, at 9 a.m. Eastern Time (6:00 a.m. PT) |
|
|
Dial In Number: |
To access the live call, dial 800-367-2403 (US and Canada) or
334-777-6978 (International) and give the participant pass code
4492256. |
|
|
Webcast: |
To access the live and replay webcast, please visit the
investor relations section of Stereotaxis’ website at
http://ir.stereotaxis.com/ |
|
|
Call Replay: |
A phone replay of the call will be available for one week
beginning approximately two hours following the end of the call
through November 21, 2019. To access the replay dial-in
information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative
robotic technologies designed to enhance the treatment of
arrhythmias and perform endovascular procedures. Its mission is the
discovery, development and delivery of robotic systems,
instruments, and information solutions for the interventional
laboratory. These innovations help physicians provide unsurpassed
patient care with robotic precision and safety, improved lab
efficiency and productivity, and enhanced integration of procedural
information. Stereotaxis’ robotic technology has received various
regulatory clearances in the United States, European Union, Japan,
Canada, China, and elsewhere. The Stereotaxis Genesis™ RMN System
is CE marked and will become available in other global geographies
subject to regulatory approvals. Stereotaxis Imaging Model S is CE
marked and FDA cleared. For more information, please visit
www.stereotaxis.com.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024